{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-346796","form_type":"8-K","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2026-08-12T20:02:53+00:00","discovered_at":"2026-08-12T20:04:00.552774+00:00","generated_at":"2026-08-12T20:04:24.605553+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sangamo files June monthly operating report; cash $14.38M, net loss $3.76M in Chapter 11","bullets":["Chapter 11 filed June 23, 2026; case No. 26-10989 in Delaware; stock now OTC under SGMOQ.","Cash balance $14.38M at June 30, 2026; drew $10.5M under initial DIP facility during June.","June net loss $3.76M; gross income $108,953, G&A $1.10M, reorganization items $2.01M.","Prepetition unsecured debt $78.13M; total liabilities $89.15M; total assets $153.09M.","73 full-time employees as of June 30; professional fees and DIP financing approved by court."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-346796","json":"https://secwatch.observer/filing/0001193125-26-346796.json","markdown":"https://secwatch.observer/filing/0001193125-26-346796.md","text":"https://secwatch.observer/filing/0001193125-26-346796.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000119312526346796/0001193125-26-346796-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000119312526346796/d21956d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T20:04:24.605553+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}